Related Experiment Video
Updated: May 4, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein
Gertrud U Rey1, Congrong Miao1, Hayat Caidi1
1National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.
Respiratory syncytial virus (RSV) vaccines are crucial. This study shows that RSV G peptide vaccines can reduce enhanced disease in mice previously vaccinated with formalin-inactivated RSV, a promising finding for future vaccine development.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Respiratory syncytial virus (RSV) is a significant respiratory pathogen and a priority for vaccine development.
- A historical concern with non-live RSV vaccines, such as formalin-inactivated RSV (FI-RSV), is the potential for vaccine-enhanced respiratory disease.
- Antibodies targeting the RSV G protein have shown potential in mitigating RSV-associated immunopathology.
Purpose of the Study:
- To investigate whether RSV G protein peptide vaccines can prevent enhanced respiratory disease in a mouse model.
- To determine if antibodies induced by G protein peptides can confer protection against enhanced disease following FI-RSV vaccination.
Main Methods:
- Mice were vaccinated with FI-RSV and subsequently immunized with RSV G protein peptides.
- Following immunization, mice were challenged with live RSV.
- Pulmonary inflammation and eosinophilia were assessed as indicators of enhanced disease.
Main Results:
- Mice that received FI-RSV vaccination followed by RSV G peptide immunization showed a significant reduction in enhanced disease upon RSV challenge.
- The G protein peptide vaccines effectively reduced pulmonary inflammation and eosinophilia compared to control groups.
Conclusions:
- The study supports the hypothesis that targeting the RSV G protein with peptide vaccines can mitigate enhanced disease associated with non-live RSV vaccines.
- These findings highlight the critical role of the RSV G protein in disease pathogenesis and suggest G peptide vaccines as a potential strategy to improve the safety of future non-live RSV vaccines.
